Denali Therapeutics Q4 2023 GAAP EPS $(0.86) Misses $(0.81) Estimate
Portfolio Pulse from Benzinga Newsdesk
Denali Therapeutics reported a Q4 2023 GAAP EPS of $(0.86), missing the consensus estimate of $(0.81) by 6.17%.
February 27, 2024 | 1:18 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Denali Therapeutics reported a Q4 2023 GAAP EPS of $(0.86), missing the consensus estimate of $(0.81) by 6.17%.
Missing the consensus estimate on earnings per share (EPS) typically leads to negative investor sentiment in the short term, potentially causing a decrease in stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100